Phase Ib results of ProSTAR: CPI-1205, EZH2 inhibitor, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration-resistant prostate cancer (mCRPC)Mary-Ellen Taplin,Arif Hussain,Satish Shah,Neal D. Shore,William Jeffery Edenfield,Oliver A. Sartor,Luke T. Nordquist,Manish Agrawal,William Clark,David R. Wise,William K. Oh,Mark T. Fleming,James E. Butrynski,Gurkamal S. Chatta,Manojkumar Bupathi,Claudia Lebedinsky,Adrian Senderowicz, Jian Li,Gozde Colak,David Nash,Patrick Trojer,William D. Bradley,Jessica Piel,Emmanuel S. AntonarakisCANCER RESEARCH（2019）引用 11|浏览20暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
